Last reviewed · How we verify
Zaditor®
Zaditor is a selective H1-receptor antagonist and mast cell stabilizer that prevents allergic responses in the eye.
Zaditor is a selective H1-receptor antagonist and mast cell stabilizer that prevents allergic responses in the eye. Used for Allergic conjunctivitis (itching of the eye due to allergies).
At a glance
| Generic name | Zaditor® |
|---|---|
| Sponsor | Bausch & Lomb Incorporated |
| Drug class | H1-receptor antagonist / mast cell stabilizer |
| Target | H1 receptor; mast cell stabilization |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology / Allergy |
| Phase | FDA-approved |
Mechanism of action
Zaditor works through dual action: it blocks histamine H1 receptors on ocular tissues to prevent histamine-mediated allergic symptoms, and it stabilizes mast cells to reduce the release of inflammatory mediators. This combination provides rapid symptom relief and sustained prevention of allergic conjunctivitis.
Approved indications
- Allergic conjunctivitis (itching of the eye due to allergies)
Common side effects
- Headache
- Conjunctival injection
- Eye irritation
- Mydriasis
Key clinical trials
- Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis (PHASE3)
- Evaluating Quality of Life Benefits of ACUVUE® Theravision® With Ketotifen in Subjects With Ocular Allergies (NA)
- A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle (PHASE3)
- A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model. (PHASE3)
- Safety and Comfort of AL-4943A Ophthalmic Solution (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |